Open AccessPopulation-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model–Based Analysis
Author(s) -
Nicolas Van de Velde,
MarieClaude Boily,
Mélanie Drolet,
Eduardo L. Franco,
MarieHélène Mayrand,
Erich V. Kliewer,
François Coutlée,
JeanFrançois Laprise,
Talía Malagón,
Marc Brisson
Publication year - 2012
Publication title -
jnci journal of the national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.797
H-Index - 356
eISSN - 1460-2105
pISSN - 0027-8874
DOI - 10.1093/jnci/djs395
Subject(s) - medicine , bivalent (engine) , population , vaccine efficacy , vaccination , cervical intraepithelial neoplasia , cervical cancer , oncology , gynecology , immunology , environmental health , cancer , metal , chemistry , organic chemistry
Bivalent and quadrivalent human papillomavirus (HPV) vaccines are now licensed in several countries. Furthermore, clinical trials examining the efficacy of a nonavalent vaccine are underway. We aimed to compare the potential population-level effectiveness of the bivalent, quadrivalent, and candidate nonavalent HPV vaccines.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom